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Pomocysteine Hypothesis for
therothrombotic Cardiovascular Disease
ot Validated
anjay Kaul, MD,*† Andrew A. Zadeh, MD,*† Prediman K. Shah, MD*†
os Angeles, California
Homocysteine has been implicated in promoting atherosclerotic and thrombotic vascular
disease. During the last decade, the utility of homocysteine in predicting risk for athero-
thrombotic vascular disease has been evaluated in several observational studies in a large
number of patients. These studies show that the overall risk for vascular disease is small, with
prospective, longitudinal studies reporting a weaker association between homocysteine and
atherothrombotic vascular disease compared to retrospective case-control and cross-sectional
studies. Furthermore, randomized controlled trials of homocysteine-lowering therapy have
failed to prove a causal relationship. On the basis of these results, there is currently insufficient
evidence to recommend routine screening and treatment of elevated homocysteine concen-
trations with folic acid and other vitamins to prevent atherothrombotic vascular disease. This
review outlines the metabolism and pathophysiology of homocysteine, highlights the results
of homocysteine observational and interventional trials, and presents areas of uncertainty and
potential future work. (J Am Coll Cardiol 2006;48:914–23) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.086College of Cardiology Foundation
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ihe homocysteine “hypothesis of arteriosclerosis” was
rst proposed by McCully (1) in 1969, when he observed
remature atherothrombosis of the peripheral, coronary,
nd cerebral vasculature in children with homocystinuria,
n inborn error in methionine metabolism. In 1976,
ilcken and Wilcken (2) provided the first evidence of a
elationship between abnormal homocysteine metabolism
nd coronary artery disease (CAD) in the general popu-
ation. Since these seminal observations, results from a
arge number of laboratory and epidemiologic investiga-
ions have implied a pathogenetic role for homocysteine
n atherosclerotic cardiovascular disease (CVD) (3– 8).
Ideally, the declaration of homocysteine as a causal risk
actor for CVD should be predicated on fulfilling 3
equirements: 1) establishment of a strong, consistent,
nd independent association between elevated homocys-
eine levels and adverse cardiovascular outcomes, derived
rom robust epidemiologic assessment; 2) elucidation of a
oherent mechanism by which homocysteine directly
romotes atherothrombosis; and 3) demonstration of
ardiovascular risk modification based on prospective,
andomized intervention trials aimed at reducing homo-
ysteine levels. In this review, we deconstruct the current
vidence base for homocysteine’s role in atherosclerotic
ascular disease with respect to these criteria. Our anal-
sis shows that the current data do not support the
alidity of the homocysteine hypothesis.
From the *Division of Cardiology, Cedars-Sinai Medical Center and the †David
effen School of Medicine, University of California, Los Angeles, California. Drs.
aul and Zadeh contributed equally to this work.t
Manuscript received January 24, 2006; revised manuscript received March 28,
006, accepted April 4, 2006.OMOCYSTEINE METABOLISM AND
ETERMINANTS OF ELEVATED HOMOCYSTEINE
omocysteine is a sulfur-containing amino acid produced
n the metabolism of the essential amino acid methionine
3). Homocysteine is metabolized through 1 of 2 vitamin-
ependent pathways—remethylation (requiring folate and
itamin B12), which converts homocysteine back to methi-
nine, and transsulfuration (requiring vitamin B12), which
onverts homocysteine to cysteine and taurine (Fig. 1). An
lternative remethylation pathway in the liver and kidney
tilizes betaine instead of folate (3,4).
Total plasma (or total serum) homocysteine (tHcy) re-
ects the combined pool of free, bound, reduced, and
xidized forms of homocysteine in the blood (3). Normal
Hcy levels range between 5 and 15 mol/l (12 mol/l
eing the upper reference limit for populations on a folic-
cid-fortified diet, as in North America) with elevations of
6 to 30 mol/l, 31 to 100 mol/l, and 100 mol/l
lassified as mild, moderate, and severe hyperhomocysteine-
ia, respectively (9). Blood levels of tHcy are optimally
easured during fasting. However, measurement after me-
hionine load may be more sensitive in identifying mild
isturbances in homocysteine metabolism (10).
Several dietary and lifestyle factors, genetic defects, nu-
ritional deficiencies, and other etiologies can cause eleva-
ions in homocysteine (3,4) (Fig. 1). A thermolabile variant
f methylene tetrahydrofolate reductase (MTHFR) with
educed enzymatic activity (C677T mutation) is the most
ommon form of genetic hyperhomocysteinemia (5% to
4% of the general population is homozygous for this
utation). However, an association of this mutation with
ncreased CVD risk is manifest only in populations charac-
erized by low baseline folate levels (8). Deficiency of folic
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September 5, 2006:914–23 Homocysteine and Atherothrombosiscid, vitamin B6, and vitamin B12 accounts for the majority
two-thirds) of cases of elevated homocysteine in the general
opulation (11).
The therapeutic options for lowering elevated homocys-
eine are summarized in Figure 1. Folate supplementation
0.5 to 5 mg/day) significantly reduces tHcy concentration
Abbreviations and Acronyms
CAD  coronary artery disease
CVD  cardiovascular disease
HOPE-2  Heart Outcomes Prevention Evaluation-2
trial
IHD  ischemic heart disease
MACE  major adverse cardiac event
MI  myocardial infarction
MTHFR  methylene tetrahydrofolate reductase
NORVIT  Norwegian Vitamin Trial
tHcy  total homocysteine
VISP  Vitamin Intervention for Stroke Prevention
study
igure 1. Outline of methionine/homocysteine metabolism, causes of hype
oenzymes and substrates: THF, tetrahydrofolate; B2, riboflavin; B6, vitamin B6 a
obalamin. Intermediate metabolite: DMG, dimethylglycine. Adapted, with pey 25% in patients with mild to moderate hyperhomocys-
einemia (12). Supplementation with vitamin B12 produces
small additional effect (7%), whereas vitamin B6 treatment
lone only reduces post-methionine load concentrations
12). Betaine (trimethylglycine) reduces fasting homocys-
eine by 12% to 20% without altering folate levels (13).
holine, a precursor to betaine, decreases fasting and post-
ethionine load homocysteine levels. Both betaine and choline
an have an adverse impact on lipid profile.
PIDEMIOLOGICAL EVIDENCE
INKING HOMOCYSTEINE AND
THEROTHROMBOTIC VASCULAR DISEASE
bservational studies. Case-control and prospective stud-
es demonstrate a graded and independent association be-
ween tHcy and cardiovascular risk. The results of these
nvestigations have been compiled into 2 large, independent
eta-analyses (7,8).
ocysteinemia, and therapeutic options for lowering homocysteine. Vitaminrhom
s its biologically active form, i.e., pyridoxal 5=-phosphate; and B12, methyl
rmission, from Malinow et al. (48).
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Homocysteine and Atherothrombosis September 5, 2006:914–23The Homocysteine Studies Collaboration (8) pooled
vidence from 12 prospective and 18 retrospective studies
rom 1966 to 1999. A total of 5,073 CAD events and 1,113
troke events were observed among 16,786 healthy individ-
als. The results showed that a 25% increase in the serum
omocysteine concentration (an increase of approximately 3
mol/l) is associated with a 49% higher risk of ischemic
eart disease (IHD) in the retrospective studies. In contrast,
weaker association was observed in the prospective studies
20% risk increase) (Table 1). With respect to stroke, the
trength of association was reversed—a nonsignificant 16%
igher risk in retrospective studies compared with a signif-
cant 30% higher risk in prospective studies (Table 1). After
djustment for confounding by known cardiovascular risk
actors and regression dilution bias, the strength of associ-
tion was attenuated—from a 49% to a 12% increase in the
isk of IHD and from a 30% to a 23% increase in the risk of
troke (Table 1).
An independent meta-analysis of 72 retrospective studies
y Wald et al. (7), in which the prevalence of a mutation in
he MTHFR gene was determined in 16,849 people,
howed increased odds of IHD and stroke for homozygotes
or the mutation (TT) compared with wild-type homozygotes
Table 1). A 5-mol/l increase in tHcy level was associated
ith an increased risk of IHD and stroke (Table 1). Similar
o the findings observed in the previous meta-analysis, the
ncrease in adjusted risk for IHD was lower in the prospec-
ive (19%) compared with the retrospective studies (43%)
Table 1). On the basis of this meta-analysis, a decrease in
erum homocysteine of 3 mol/l (achievable by daily intake
f about 0.8 mg folic acid) would reduce the risk of IHD by
6% and stroke by 24% (8).
estenosis studies. Despite the potential involvement of
yperhomocysteinemia in the restenotic process suggested
y experimental studies (14,15), clinical studies have failed
able 1. Summary of Meta-Analyses Studying Relationship of Se
n-Stent Restenosis
Source
Study Types
(No. of Studies)
omocysteine Studies Collaboration, 2002 (6) Retrospective (18)
Prospective (12)
ald et al. 2002 (7) Retrospective (72)
Prospective (20)
omocysteine and In-Stent Restenosis Pooled
Analysis, 2005 (16)
Retrospective (4)
Denotes a 3-mol/l increase in serum homocysteine concentration between study gr
Signifies a 5-mol/l increase in serum homocysteine concentration between stu
ypercholesterolemia, diabetes, etc., and regression dilution bias.
CI  confidence interval; IHD  ischemic heart disease; MTHFR  methylene tetraho demonstrate this relationship after stent implantation. In
recently published report of pooled analysis of 1,429
atients, 383 (26.8%) had hyperhomocysteinemia (15
mol/l) that was not associated with higher rates of in-stent
estenosis (29.0% vs. 29.5%, p  0.47) (16) (Table 1).
ietary studies. Finally, large observational studies cor-
elating diet with long-term risk of vascular events among
ore than 50,000 healthy individuals suggest that a
ecreased dietary intake of folate is associated with an
ncreased risk of ischemic stroke and cardiovascular
vents, independent of major lifestyle and other dietary
actors (17).
In summary, the totality of evidence from epidemiologic
bservations suggests a graded and independent relationship
etween homocysteine and atherothrombotic vascular risk.
tronger associations are found in studies that used less
obust methods (case-control), and weaker associations were
eported by more robust prospective cohort studies. It is
uite plausible that the relationship between hyperhomo-
ysteinemia and CVD is indirect, and is confounded by
ther factors (e.g., deficiencies of folate, vitamin B12, or
itamin B6 and renal insufficiency) that influence both
omocysteine levels and cardiovascular risk. Results from
ong-term follow-up of the Kuopio Ischemic Heart Disease
isk Factor Study (18) demonstrate that low folate concen-
rations were associated with increased risk of CAD events
ndependent of homocysteine concentrations. Therefore,
omocysteine may be overrated as a causal risk factor for
therothrombotic vascular disease. Findings that tHcy levels
ypically rise after an acute vascular event in response to
issue damage or repair and remain elevated for months
ollowing the acute event (19,20) suggest that elevated
omocysteine may be a “consequence” rather than a “cause”
f vascular disease (20).
Homocysteine and Ischemic Heart Disease, Stroke, and
ple Size Variable Rate Ratio (95% CI)
,761 3mol/l tHcy* 1.49 (1.41–1.61): IHD
1.16 (0.99–1.37): stroke
,025 3mol/l tHcy* 1.20 (1.12–1.30): IHD
1.30 (1.11–1.52): stroke
1.12 (1.04–1.20): IHD‡
1.23 (1.05–1.45): stroke‡
,849 MTHFR (TT vs. wild-type) 1.21 (1.06–1.39: IHD
1.31 (0.80–2.15): stroke
5mol/l tHcy† 1.43 (1.11–1.84): IHD
1.65 (0.66–4.13): stroke
,820 5mol/l tHcy† 1.19 (1.12–1.25): IHD‡
1.32 (1.18–1.49): stroke‡
383 15mol/l tHcy 1.10 (0.85–1.43): in-stent
restenosis
,046 15mol/l tHcy
the original data have been modified to show higher risk with higher homocysteine).
oups. ‡Adjusted for traditional cardiovascular risk factors such as hypertension,rum
Sam
7
9
16
3
1
oups (
dy grydrofolate reductase; tHcy  total homocysteine levels.
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September 5, 2006:914–23 Homocysteine and AtherothrombosisATHOPHYSIOLOGIC MECHANISMS LINKING
OMOCYSTEINE AND ATHEROTHROMBOTIC
ASCULAR DISEASE
he mechanisms by which elevated homocysteine im-
airs vascular function are not completely understood.
aboratory investigations have revealed several potential
echanisms (Table 2), including impairment of endo-
helial function (21,22), oxidation of low-density lipids
23), increased monocyte adhesion to the vessel wall (4),
ncreased lipid uptake and retention (4), activation of the
nflammatory pathway (4,24), stimulatory effects on
mooth-muscle proliferation (4), and thrombotic ten-
ency mediated by activation of coagulation factors (21)
nd platelet dysfunction (25). The atherogenic and
hrombogenic potentials of homocysteine have been im-
licated in promoting endothelial dysfunction induced by
cute hyperhomocysteinemia after methionine loading in
uman subjects (26), facilitating the progression of ath-
rosclerotic plaque in apolipoprotein E-deficient mice
24), promotion of prothrombotic state (4), and exacer-
ation of intimal hyperplasia and restenosis after balloon
njury of arteries (14,15).
These findings provide a coherent and biologically plau-
ible basis for a direct role for homocysteine in promoting
therothrombosis.
able 2. Pathophysiologic Mechanisms Relating Homocysteine
o Atherothrombosis
therogenesis
● Induces vascular inflammation via expression of TNF- and iNOS
● Increases oxidative stress
● Induces DNA hypomethylation and gene expression for cell growth
and differentiation
● Promotes the oxidation of low-density lipoprotein
● Enhances uptake of modified lipoproteins by macrophages
● Induces endothelial dysfunction via increased oxidant stress,
increased ADMA, increased inflammation, and decreased
bioavailability of NO
● Promotes lipid accumulation via induction of HMG-CoA reductase
● Stimulates vascular smooth muscle cell (VSMC) DNA synthesis and
proliferation
● Directly toxic to endothelial cells
hrombogenesis
● Induces tissue factor activity
● Promotes leukocyte–endothelial interactions via MCP-1 and IL-8
expression
● Enhances endothelial-cell-associated factor V activity
● Impairs inactivation of factor Va by activated protein C
● Inhibits the binding of antithrombin III to the endothelium
● Reduces endothelial binding sites for tissue plasminogen activator
● Enhances binding of lipoprotein (a) to fibrin
● Decreases cell surface thrombomodulin and protein-C activation
● Increases platelet aggregation
DMA  asymmetric dimethylarginine; HMG-CoA  3-hydroxy-3-
ethylglutaryl-CoA; IL  interleukin; iNOS  inducible nitric acid synthase; MCP n
onocyte chemoattractant protein; NO  nitric oxide; VSMC  vascular smooth
uscle cell.MPACT OF LOWERING ELEVATED HOMOCYSTEINE
N ATHEROTHROMBOTIC VASCULAR DISEASE
everal randomized controlled trials have investigated the
ffect of folic acid and/or vitamins B6 and B12 supplemen-
ation on multiple surrogate markers of CVD, restenosis,
nd serious clinical outcome events, such as stroke, myocar-
ial infarction (MI), or death.
mpact on surrogate outcomes. Several lines of evidence
emonstrate that lowering of homocysteine may favorably
lter surrogate cardiovascular outcomes. First, supplemen-
ation with folate and vitamin B12 has been shown to
revent post-prandial endothelial dysfunction in subjects
ith normal homocysteine levels and to improve endothelial
unction in patients with hyperhomocysteinemia, CAD, or
isk factors for CAD (27). It is not clear whether this effect
s directly related to lowering of homocysteine or mediated
ia an indirect homocysteine-independent mechanism
5,28–30). For example, folate stimulates tetrahydrobiop-
erin regeneration (28) and counteracts homocysteine inhi-
ition of endothelial nitric oxide synthase (29), thereby
mproving nitric oxide bioavailability. In addition, vitamin
6, via its effects on the glutathione antioxidation system
30), could attenuate the oxidant stress associated with
yperhomocysteinemia, thereby leading to improved endo-
helial function. Second, vitamin treatment decreases the
ncidence of positive stress electrocardiograms in healthy
iblings of patients with atherothrombotic disease without
mproving peripheral arterial abnormalities (Table 3) (31).
hird, patients treated with a combination of folate, vitamin
12, and vitamin B6 show a significant regression in carotid
laque area, even those with homocysteine concentrations
14 mol/l (32). In renal transplant recipients, treatment
ith B-vitamins decreased carotid intima-media thickness
y 32% compared to a 23% increase in those treated with
lacebo (Table 3) (33).
In contrast to the positive studies, a recent study failed to
emonstrate any beneficial effect of homocysteine lowering
n inflammatory markers such as C-reactive protein, soluble
ntercellular adhesion molecule-1, oxidized low-density li-
oprotein, and autoantibodies against oxidized low-density
ipoprotein that have been implicated in atherothrombosis
34). The null findings were observed despite a 4-fold
ncrease in serum folate and a 25% reduction in homocys-
eine levels.
mpact on clinical outcomes. The evidence that lowering of
omocysteine by vitamin supplementation reduces cardiovas-
ular clinical outcomes in patients with elevated homocysteine
omes primarily from secondary prevention randomized tri-
ls—2 evaluating the impact on restenosis and 3 evaluating the
mpact on hard clinical outcomes (Table 3).
omocysteine-lowering and restenosis. A prospective,
ouble-blinded, randomized clinical trial in 205 patients with
aseline normal-to-mild hyperhomocysteinemia (11 mol/l)
rovided the first evidence of reduction of angiographic reste-
osis 6 months after coronary angioplasty and/or bare-metal
s
r
i
b
e
m
w
A
M
r
i
w
t
c
v
l
r
m
t
0
e
T
C
S
C
*
r
f
a
a ISP 
918 Kaul et al. JACC Vol. 48, No. 5, 2006
Homocysteine and Atherothrombosis September 5, 2006:914–23tenting associated with vitamin supplementation (35). The
estenosis benefit was primarily observed in patients undergo-
ng angioplasty (10.3% vs. 41.9%, p  0.001), but not
are-metal stenting (20.6% vs. 29.9%, p  0.32).
An extension of this study (Swiss Heart Study) aimed to
valuate the impact of homocysteine-lowering therapy on a
ajor adverse cardiac event (MACE) in 553 patients treated
ith angioplasty, with or without stenting (Table 2) (36).
lthough therapy did show significant risk reduction in
ACE compared to placebo, this was primarily driven by a
eduction in target lesion revascularization, with no signif-
able 3. Summary of Randomized Controlled Trials Investigatin
ardiovascular Outcomes
Study
Sample
Size
Study
Duration
urrogate outcomes
Vermeulen et al., (31) 2000 (volunteers) 78 24 months
80
Marcucci et al., (38) 2003
(post-renal transplant)
25 6 months
28
linical outcomes
Schnyder et al., (35) 2001
(post-PTCA/stenting)
272 6 months 1
281
The Swiss Heart Study, Schnyder et al.,
(36) 2002 (post-PTCA/stenting)
272 12 months 1
281
Lange et al., (37) 2004 (post-stenting) 316 6 months 1
320
VISP Trial, (40) 2004 (post-stroke) 1,827 24 months 2
1,853 0
NORVIT trial, (42) 2005 (post-MI) 937 40 months 0.
935 0
934
943
HOPE trial, (43) 2006 (vascular
disease, diabetes)
2,758 60 months 2
2,764
Patients received 1 initial intravenous bolus of 1 mg FA, 5 mg vitamin B6, and 1 m
esults are shown as comparisons between groups A and B vs. groups C and D. ‡Th
or each trial is shown in bold.
CIMT carotid intima-media thickness; CV cardiovascular; ECG electrocardiog
dverse cardiac event; MI  myocardial infarction; NORVIT  Norwegian Vitami
ngioplasty; SCD  sudden cardiac death; TLR  target lesion revascularization; Vcant impact on nonfatal MI or death. eThe second study was also a placebo-controlled trial, in
hich Lange et al. (37) examined the effect of vitamin
herapy at higher doses on 636 patients after successful
oronary stenting with bare-metal stents. The multi-
itamin therapy successfully reduced serum homocysteine
evels, but was associated with a paradoxical increase in
estenosis (target vessel revascularization) and MACE at 6
onths, particularly in patients with homocysteine levels in
he normal range (15 mol/l) (36.2% vs. 25.3%, p 
.02), whereas slight benefits were observed in patients with
levated homocysteine (27.2% vs. 31.7%, p  NS). Clinical
Impact of Homocysteine-Lowering Therapy on
Treatment Groups Outcomes Rate Ratio (95% CI)
mg FA, 250 mg B6 0.4 (0.2–0.9):  stress ECG
vs. 0.9 (0.6–1.3): ankle-brachial index
placebo 1.0 (0.3–4.1): PAD
0.9 (0.5–1.6): carotid stenosis
FA, 50 mg B6, 4 mg B12 32  13% decrease in CIMT
vs.
placebo 23  21% increase in CIMT
FA, 10 mg B6, 0.4 mg B12 0.46 (0.28–0.73): restenosis
vs. 0.52 (0.28–0.98): MACE
placebo 0.48 (0.25–0.94): TLR
FA, 10 mg B6, 0.4 mg B12 0.68 (0.48–0.96): MACE
vs. 0.62 (0.40–0.97): TLR
lacebo ( 6 months) 0.60 (0.24–1.51): nonfatal MI
0.52 (0.13–2.04): cardiac death
0.54 (0.16–1.70): mortality
FA, 48 mg B6, 60 g B12* 1.30 (1.0–1.69): restenosis
vs. 1.53 (1.03–2.28): MACE
placebo
FA, 25 mg B6, 0.4 mg B12 1.0 (0.8–1.3): recurrent stroke
vs. 0.9 (0.7–1.2): MACE
g FA, 0.2 mg B6, 6 g B12 0.9 (0.7–1.1): mortality
FA, 40 mg B6, 0.4 mg B12
p A)
1.08 (0.93–1.25) MI, stroke, SCD†
FA, 0.4 mg B12 (group B) 1.02 (0.83–1.26): death†
40 mg B6 (group C) 1.06 (0.91–1.24): MI†
Placebo (group D) 1.02 (0.68–1.51): stroke†
1.22 (0.88–1.70): cancer†
1.22 (1.00–1.50): MI, stroke, SCD‡
1.21 (0.91–1.61): death‡
1.23 (0.99–1.52): MI‡
0.83 (0.47–1.47): stroke‡
1.02 (0.65–1.58): cancer‡
FA, 50 mg B6, 1.0 mg B12 0.95 (0.84–1.07): CV death, MI, stroke
vs. 0.96 (0.81–1.13): CV death
placebo 0.98 (0.85–1.14): MI
0.75 (0.59–0.97): stroke
tamin B12 given on day 1. The oral dosages listed were continued thereafter. †The
lts are shown as comparisons between group A vs group D. The primary end point
A folic acid; HOPEHeart Outcomes Prevention Evaluation trial; MACEmajor
l; PAD  peripheral arterial disease; PTCA  percutaneous transluminal coronary
Vitamin Intervention for Stroke Prevention study.g the
5
5 mg
mg
mg
p
.2 mg
.5 mg
.02 m
8 mg
(grou
.8 mg
.5 mg
g of vi
e resu
ram; F
n Triand points such as death and nonfatal MI were not affected
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September 5, 2006:914–23 Homocysteine and Atherothrombosisignificantly. The divergent findings of this study compared
ith previous observations may likely be related to the use
f: 1) a higher treatment dose of folate and vitamins,
specially vitamin B6 (including intravenous loading);
) 100% use of bare-metal stents (50% in past studies);
) longer lesion length; 4) lower-risk patient population
more smokers, diabetic patients, and patients with prior
Is in former studies); 5) higher serum homocysteine
evels; and 6) limited angiographic follow-up (76% com-
ared with 100%). Although the increased risk of bare-metal
tent-associated restenosis with high-dose homocysteine-
owering therapy is of some concern, it is unclear what impact
his will have in clinical practice given the current widespread
doption of drug-eluting stents over bare-metal stents in the
.S. (85% to 90% of all coronary interventions).
omocysteine lowering and hard vascular event out-
omes. Two smaller open-label studies had previously
ailed to show any beneficial effects of administration of folic
cid added to statin therapy on cardiovascular events in a
opulation of post-acute MI patients (FOLARDA [Folic
cid on Risk Diminishment After Acute Myocardial
nfarction] trial, n  283) (38) or stable CAD (the Goes
tudy, n  583) (39) despite significant lowering in homo-
ysteine levels.
Three recent large, multicenter, double-blind, random-
zed studies have evaluated the impact of homocysteine-
owering therapy for secondary prevention of stroke and MI
n high-risk individuals.
The VISP (Vitamin Intervention for Stroke Prevention)
tudy was the first large-scale randomized interventional
rial to report hard end points (40). The trial investigated
he lowering of homocysteine with high-dose compared
ith low-dose vitamin B formulation in patients with
schemic stroke. Compared to the low-dose group, treat-
ent with the high-dose formulation had no effect on
ecurrent stroke, coronary events, or deaths (Table 3). The
esults of the VISP trial were contrary to expectations and
ndicate that B-vitamins and homocysteine may not be
mportant for development of strokes. However, there are
everal limitations of the VISP trial that might preclude
rawing any definitive conclusions. First, a less-than-
xpected between-group difference of 2 mol/l in homo-
ysteine concentrations, and the enrollment of patients with
nly mild increases in baseline homocysteine concentrations
reflecting the high prevalence of vitamin supplement use
nd widespread folic acid fortification in North America
ince the initiation of the VISP trial) may have masked the
ffect of treatment on stroke risk. Second, treatment of both
roups with low-dose vitamin formulation in the 1-month
un-in phase (the dose of vitamin B12 at 2.5 the recom-
ended daily allowance) may have been sufficient to nor-
alize vitamin B12 status in most patients in the low-dose
roup, potentially resulting in dilution of the treatment
ffects. Third, the rates of recurrent strokes were lower than
nticipated in both study groups, and the follow-up period
as short (2 years). Fourth, the trial was not placebo- tontrolled, but rather a head-to-head comparison of daily
igh-dose against low-dose vitamin formulations. All of
hese factors limited the statistical power of the VISP trial
o reliably identify or exclude a modest, but clinically
mportant, therapeutic effect of vitamins.
In a post-hoc subgroup analysis confined to treatment
esponders (n  2,155), the VISP investigators recently
eported a 21% reduction in the risk of combined end point
f ischemic stroke, coronary disease, or death in the high-
ose compared with the low-dose group (unadjusted p 
.049; adjusted for age, gender, blood pressure, smoking,
nd B12 level, p  0.056) (41). Analysis of vitamin B12 blood
evels revealed that patients with a baseline B12 level  the
edian level randomized to high-dose vitamin had the best
verall outcome, and those with B12  median level assigned
o a low-dose vitamin formulation had the worst (p 0.02 for
ombined stroke, death, and coronary events; p  0.03 for
troke and coronary events). These hypothesis-generating
ata suggest that in the era of folate fortification, higher
oses of B12 and other treatments may be needed for some
atients to reduce clinical outcomes.
The NORVIT (Norwegian Vitamin Trial) was designed
s a randomized, controlled, double-blind, multicenter,
econdary prevention trial, testing the hypotheses that
ong-term (median follow-up of 40 months) treatment with
-vitamins would lower the incidence of MI, stroke, and
udden cardiac death in patients with acute MI (42). The
rial recruited 3,749 patients from Norway (where folate
ortification of food is not mandatory) who were random-
zed into 4 groups, as shown in Table 3. The NORVIT
atients were medically optimally treated (about 90% on
spirin and beta-blockers, 80% on statins) and had a 90%
ompliance.
Plasma homocysteine levels decreased by about 27% in
atients taking folic acid (whether or not they were also
aking vitamin B6) compared with vitamin B6- and placebo-
reated patients. Plasma folate levels rose 6- to 7-fold with
olic acid treatment. The primary end point occurred in
pproximately 18% of each of the placebo, folic acid 
itamin B12, and vitamin B6 groups. In the group that
eceived combination therapy (folic acid  vitamin B12 
itamin B6), however, there was a nominally significant
elative increase in the primary end point by 22% (p 0.05)
nd nonfatal MI by 30% (p  0.05), and a nonsignificant
7% decrease (p  0.52) in stroke versus placebo. The
umulative hazard ratio for the combination therapy group,
s compared with the other 3 groups, was 1.20 (95%
onfidence interval 1.02 to 1.41). Event rates, including
ndividual components of the primary end point, tended to
e higher in the folic acid  vitamin B12 group versus
itamin B6 and the placebo group (Table 3). Cancer rates
ere nonsignificantly higher in both of the folic acid groups.
ubgroup analyses showed no suggestion of benefit in any
ubgroup.
The HOPE-2 (Heart Outcomes Prevention Evaluation-2)
rial was a randomized, double-blind trial including 5,522
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Homocysteine and Atherothrombosis September 5, 2006:914–23atients 55 years of age or older with a history of vascular
isease or diabetes (43). About 70% of the study population
as recruited from the U.S. and Canada, where folate
ortification of food is mandatory. Patients were randomized
o receive a combined pill containing 2.5 mg of folic acid, 50
g of vitamin B6, and 1 mg of vitamin B12 or placebo daily
or an average of 5 years. The primary outcome was a
omposite of death from cardiovascular causes, MI, and
troke. Mean homocysteine levels decreased by 2.4 mol/l
0.3 mg/l) among those receiving the active treatment, while
slight increase of 0.8 mol/l was seen in the placebo
roup. Despite this effective homocysteine lowering, how-
ver, no significant effect was seen on the primary outcome
r the individual components except for a 25% reduction in
troke. An increase in the number of patients hospitalized
or unstable angina was observed with active treatment.
here was no difference in outcomes in any subgroups,
ncluding those from countries with or without folate
upplementation or those with higher or lower baseline
omocysteine levels.
igure 2. Bayesian analysis of the HOPE-2 trial. Triplots showing posterio
ine) from the HOPE-2 trial and informative priors (dashed line) based o
ombination therapy group vs. placebo are utilized to match the HOPE-2
osterior probabilities are estimated using priors for the primary composite
troke (log odds ratio   0.206, standard deviation   0.115), death fr
.122), and stroke (  0.246,   0.293). Probability of any effect siz
Pb, log odds ratio 0) or harm (Ph, log odds ratio 0) are shown on the right
f benefit or harm 0.950.We performed a Bayesian analysis in which prior infor-
ation derived from the NORVIT study and the empirical
vidence from the HOPE-2 trial were utilized to generate a
osterior probability using the method described previously
44). The results are shown in Figure 2 and indicate that the
robability of harm exceeds the probability of benefit for the
rimary composite end point and each of the individual
omponents except for stroke, where the probability of any
enefit exceeds 99% and the probability of 10% risk
eduction is93%. Thus, the Bayesian analysis helps clarify
he issue raised by the HOPE-2 trial investigators that “the
troke benefit may represent either an overestimate of the
eal effect or a spurious result due to the play of chance”
43), and suggests a high likelihood of stroke benefit with
omocysteine-lowering therapy compared to placebo.
hese findings are consistent with the epidemiologic obser-
ations of a stronger association of elevated homocysteine
ith stroke compared to IHD (6,7). However, they are in
ontrast to the findings of a null effect on stroke observed in
he VISP trial (40). One possible explanation for the
ck line) distributions derived from integrating evidence or likelihood (thin
rmation derived from the NORVIT study (only data from comparison of
eatment groups; see Table 3 for details) according to Bayes’ theorem (44).
point of death from cardiovascular cause, myocardial infarction (MI), and
y cause (  0.183,   0.153), myocardial infarction (  0.219,  
alculated by computing area under the curve. The probabilities of benefitr (thi
n info
trial tr
end
om an
e is cof each plot. Superiority or inferiority is inferred at a posterior probability
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September 5, 2006:914–23 Homocysteine and Atherothrombosisiscordant results may be the lack of a placebo comparison
nd a lower-than-expected between-group differential in
omocysteine level in the VISP trial, which might have
educed the likelihood of treatment differences. The results
rom ongoing trials should further clarify this issue.
The results of the NORVIT and HOPE-2 trials do not
upport the homocysteine hypothesis and suggest that
educing plasma homocysteine is not associated with benefit
nd may even tend to cause harm by increasing the risk of
VD and the risk of cancer in a manner reminiscent of the
itamins A and E intervention trials (45). A likely explana-
ion for the paradoxical findings in the NORVIT study may
e related to the high doses of vitamin B6 (40 mg), which
ay exert potentially detrimental effects, especially in the
roinflammatory milieu encountered after acute MI. Com-
ared to the group given no vitamin B6, patients treated
ith vitamin B6 experienced an overall 14% increase (p 
.09) (and a statistically significant 28% increase in current
mokers) in the primary end point, a 17% increase in MI
p  0.05), and a 19% increase in death from any cause (p 
.11) (42). Additional evidence in support of this finding is
rovided by previous reports linking high doses of vitamin
6 (48 mg) with an increased risk of in-stent restenosis (37),
ompared to a reduction in post-angioplasty restenosis
bserved with lower doses of vitamin B6 (10 mg) (35) and
ncreased inflammatory responses and inhibition of angiogen-
sis observed in laboratory investigations (46,47). Further
tudies are needed to determine whether folic acid and vitamin
6 accelerate proliferation of vascular cells and promote
rowth of cancer cells, particularly at high doses. Other
otential explanations include alteration of methylation in
ascular cells leading to a proatherogenic phenotype, meth-
lation of L-arginine to asymmetric dimethylarginine that
ay neutralize the atheroprotective effects of nitric oxide, or
imply a chance finding.
In summary, there are currently not enough reliable data
rom randomized controlled trials that show lowering
lasma homocysteine concentration prevents “hard” vascular
vents. The available evidence is either inadequate or
onflicting. Several large-scale studies totaling nearly 50,000
ubjects are currently under way in the U.S., Canada, and
urope—WENBIT (the Western Norway B-vitamin In-
ervention Trial), SEARCH (Study of Effectiveness of
dditional Reduction in Cholesterol and Homocysteine)
rial, PACIFIC (Prevention with a Combined Inhibitor and
olate in Coronary Heart Disease) trial, VITATOPS
Vitamins to Prevent Stroke) trial, and others. One will have
o await the results from these trial data before finally
onfirming or refuting the homocysteine hypothesis in
therothrombotic vascular disease.
One important point to note is that even if the interven-
ion trials do end up showing an overall positive effect on
linical outcomes, it is difficult to separate the effects of oral
olate supplementation from those of lowering homocys-
eine levels. This can be accomplished via a comparison of
olic acid treatment with betaine therapy because, although
T
toth lower circulating homocysteine (by different mecha-
isms), the latter does not influence folate levels (9). We are
ot aware of any such comparison currently under evalua-
ion in randomized trials.
ONCLUSIONS
evere elevation of homocysteine concentration in patients
ith homocystinuria leads to a high incidence of premature
therothrombotic events. In vitro and in vivo studies dem-
nstrate a plethora of biologically plausible mechanisms that
mplicate homocysteine in promoting atherosclerotic and
hrombotic vascular disease. Numerous observational stud-
es have also reported on the association between mild to
oderately elevated homocysteine levels and vascular risk in
oth the general population and in those with pre-existing
ascular disease. The overall risk for vascular disease is small,
ith prospective studies reporting weaker association com-
ared to retrospective studies. It is unclear whether a causal
elationship exists between homocysteine and cardiovascular
isk, or if homocysteine is related to other confounding
ardiovascular risk factors or is a marker of existing disease
urden. Routine screening for elevated homocysteine is not
et recommended (Table 4) (9,48–50). However, screening
ay be advisable for individuals who manifest atherothrom-
otic disease that is out of proportion to their traditional risk
actors or who have a family history of premature athero-
clerotic disease. This can be done via measurement of
asting homocysteine concentrations or by evaluation of
ost-methionine load levels. Vitamin supplementation with
olate, B6, and B12 significantly lowers homocysteine con-
able 4. Summary of Recommendations for Screening and
reatment of Elevated Homocysteine*
creening
● Routine screening not yet recommended
● Screening may be advisable in individuals who
- Manifest disease out of proportion to the traditional risk factors
- Have a family history of premature atherosclerotic disease
easurement
● Plasma (or serum) total homocysteine, fasting or post-methionine
load (more sensitive)
● Blood samples must be processed quickly (1 h at room
temperature, 8 h on ice)
● Enzymatic or immunologic assays more practical than
chromatographic assays
● Standardization required to minimize variation among laboratories
● Normal range—5 to 15mol/l (12 mol/l as upper limit with folate
fortification)
reatment
● Routine treatment with vitamin supplements not yet recommended
● Diet rich in folate and B vitamins encouraged
● Treatment with folate (0.5 to 5 mg) and vitamin B12 (0.5 to 1 mg)
may be beneficial in high-risk patients
● Therapeutic target in high-risk individuals 10 mol/l (U.S.),
13–15 mol/l (EU)
● Vitamin B12 status should be determined before starting therapy
The recommendations are based on a European Expert Panel (9), The American
eart Association Science Advisory Statement (48), the U.S. Preventive Services
ask Force (49), and the American College of Cardiology Foundation Complemen-
ary Medicine Expert Consensus Document (50).
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Homocysteine and Atherothrombosis September 5, 2006:914–23entration and has also been shown to alter surrogate
ardiovascular end points. Currently, there is no evidence
hat vitamin B supplementation reduces cardiovascular risk,
nd there may even be a suggestion of potential harm with
reatment with high-dose vitamin B. These findings have
rought renewed scrutiny to homocysteine’s role in athero-
hrombotic vascular disease. Whether homocysteine is caus-
tive in the pathogenesis of atherothrombotic vascular
isease will have to await the completion of a number of
arge, randomized controlled trials currently studying the
ffect of homocysteine-lowering vitamins on cardiovascular
nd points. Until then, the status of homocysteine as a risk
actor for vascular disease remains unvalidated.
eprint requests and correspondence: Dr. Sanjay Kaul, Division
f Cardiology, Cedars-Sinai Medical Center, 8700 Beverly Bou-
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